Stents Market

Stents Market Analysis

The stents market is valued at USD 15.05 billion in 2025 and is forecast to reach USD 18.91 billion by 2030, expanding at a 4.67% CAGR. Sustained procedure volumes in coronary artery disease, wider adoption of minimally invasive peripheral interventions and steady product launches are keeping revenue on an upward trajectory. Consolidation among leading manufacturers is improving global reach and distribution efficiency, while health-system migration toward outpatient settings is reshaping procurement dynamics. Policymaker support for early discharge and bundled payments is accelerating purchases of devices that shorten hospital stays, driving hospitals and ambulatory surgical centers to upgrade stent inventories. In parallel, artificial-intelligence tools for vessel sizing and real-time decision support are enhancing implantation accuracy and reducing costly complications, reinforcing long-term demand in the stents market.

Global Stents Market Trends and Insights

Increasing Prevalence of Coronary & Peripheral Arterial Disease

Peripheral arterial disease affects an estimated 200–250 million people worldwide and shows marked variation in regional prevalence, ranging from 5.6% in North America to 14.5% in South-Central Asia.^{[1]European Journal of Preventive Cardiology, “Global Prevalence of Peripheral Artery Disease,” academic.oup.com} Demographic aging and persistent smoking and hypertension rates—contributing 45.6% and 35.1% of peripheral disease risk respectively—are sustaining a large pool of candidates for vascular interventions. As diagnostics improve and awareness rises in emerging economies, demand for both coronary and peripheral stents strengthens, positioning disease prevalence as the prime long-term growth catalyst for the stents market.

Rapid Uptake of Transradial PCI & Day-Case Procedures

Transradial access adoption climbed from 15.9% to 69.1% across recent study periods, reducing bleeding events and enabling same-day discharge protocols. The American Heart Association endorsed transradial approaches for peripheral interventions in 2025, broadening clinical applications. Ambulatory surgical centers billing for PCI increased from 30 sites in 2019 to 65 in 2023, illustrating procedure migration away from inpatient settings.^{[2]AORN, “Cardiology Codes ASC Leaders Need to Know,” aorn.org}These patterns are accelerating device demand among outpatient providers and reinforcing value-based care initiatives in the stents market.

Technological Shift to Polymer-Free DES & Bioresorbables

Abbott’s Esprit BTK scaffold became the first FDA-approved dissolving stent for below-the-knee disease in 2024, highlighting momentum behind polymer-free drug-eluting and bioresorbable technologies. Peer-reviewed data show significantly lower inflammation and improved vessel healing versus permanent polymers. Such innovations align with the “leave nothing behind” philosophy, differentiate competitor offerings and are expected to raise the innovation benchmark across the stents market.

AI-Driven Precision Sizing & Deployment Platforms

The FLAVOUR II trial demonstrated that AI-derived fractional flow reserve delivered outcomes on par with intravascular ultrasound while simplifying workflows. HeartFlow’s automated CT analysis provides plaque morphology and optimal sizing guidance, improving operator confidence during stent deployment. Medtronic’s USD 75 million investment in CathWorks signals strategic commitment to AI-enabled diagnostics. These platforms enhance procedural outcomes and standardize decision-making, supporting sustained adoption in the stents market.

Stringent Multi-Region Approval Timelines

Manufacturers must reconcile divergent regulatory pathways as the FDA aligns Quality System Regulation amendments with ISO 13485 while Europe enforces Medical Device Regulation, extending time-to-market. Emerging countries introduce additional clinical evidence requirements, forcing companies to stagger launches and increasing compliance costs. Large incumbents with robust regulatory teams can absorb delays, but smaller innovators face barriers that may slow new entrants into the stents market.

High and Rising Product Recall Costs

Recent Class I recalls—Medtronic’s Pipeline Vantage and Philips’ Tack System—underscore the financial and reputational impact of safety events.^{[3]U.S. Food and Drug Administration, “Class 1 Device Recall Medtronic Pipeline Vantage Embolization Device,” fda.gov} Boston Scientific’s recall of the Obsidio embolic device resulted in multiple injuries and fatalities, elevating scrutiny and insurance premiums. Ongoing post-market surveillance investments redirect R&D budgets and compress margins, tempering innovation momentum across the stents market.

Segment Analysis

By Product: Coronary Dominance Amid Peripheral Acceleration

Coronary stents accounted for 55.12% of stents market share in 2024 on the back of entrenched procedure volumes in multivessel disease. Drug-eluting models featuring ultrathin struts and biodegradable polymers remain the default choice, while bare-metal designs fulfill niche needs that require shorter dual antiplatelet therapy. Peripheral stents, however, are forecast to grow at a 7.34% CAGR, driven by expanding treatment indications for iliac and femoropopliteal lesions and better device trackability in tortuous anatomy. Abbott’s FDA nod for a bioresorbable scaffold below the knee illustrates momentum toward “leave nothing behind” options in peripheral disease.

The stents market size for peripheral interventions is projected to expand steadily as screening programs and duplex ultrasound accessibility improve in emerging economies. Stent grafts for complex aortic aneurysms continue to evolve with branched and fenestrated designs that reduce endoleak risk, while neurovascular flow-diverters capture attention for wide-necked aneurysms. Manufacturers are integrating hydrophilic coatings and AI-enabled deployment feedback to improve outcomes in difficult vascular territories.

By Material: Metallic Foundation With Polymeric Innovation

Metallic biomaterials remained the backbone of the stents market, claiming 63.24% revenue in 2024 because cobalt-chromium alloys offer high radial strength and corrosion resistance. Stainless steel retains a cost advantage in price-sensitive segments. Nonetheless, polymeric scaffolds are the fastest-advancing category at an 8.68% CAGR, reflecting clinical enthusiasm for biodegradable solutions that minimize chronic inflammation. Magnesium-based constructs exhibit 2.8% platelet adherence versus 5.8% for stainless steel in preclinical models, indicating lower thrombogenicity.

Natural biomaterial coatings such as recombinant humanized collagen foster rapid endothelialization and are likely to carve out specialized niches for drug-free devices. Controlled-release polymer matrices now enable synchronized drug elution with scaffold resorption, addressing previous concerns over mechanical integrity. Economies of scale and manufacturing advances will continue to lower production costs, helping premium polymeric devices penetrate mainstream segments of the stents market.

By Application: CAD Leadership Challenged by Neurovascular Growth

Coronary artery disease accounted for 48.36% of total procedures in 2024 thanks to established reimbursement and long clinical heritage across regions. Neurovascular interventions, however, are pacing fastest at a 7.67% CAGR as expanded time windows and improved recanalization rates boost thrombectomy adoption. Flow-diverting stents and braided constructs tailored for curved intracranial vessels are enabling minimally invasive stroke treatment. Peripheral arterial disease procedures are also climbing, particularly below the knee where restenosis rates historically limited success.

Non-vascular applications, including gastrointestinal strictures and tracheobronchial obstructions, remain niche but highlight the breadth of material science advances. Future growth in endoluminal applications will depend on development of migration-resistant designs and drug-free surface modifications that cut infection risk, expanding the clinical footprint of the stents market.

By End User: Hospital Consolidation Amid ASC Migration

Hospitals continued to dominate procurement with 57.25% of global revenue in 2024 thanks to emergency readiness, hybrid operating theaters and multidisciplinary teams. Nevertheless, ambulatory surgical centers are projected to grow at an 8.91% CAGR, supported by CMS reimbursement additions that permit same-day PCI and peripheral procedures. Private-equity roll-ups of cardiology practices—342 locations acquired between 2021 and 2023—are centralizing purchasing, creating bargaining power and fostering standardized device portfolios. Cardiac catheterization laboratories in community hospitals still handle complex cases requiring hemodynamic monitoring, ensuring a balanced demand landscape in the stents market.

Geography Analysis

North America’s stents market size stood at USD 5.19 billion in 2025, driven by 500,000 annual PCI procedures, sophisticated catheter laboratories and early adoption of AI-guided sizing tools. Favorable reimbursement and clinical guideline updates that endorse day-case PCI support continuous device refresh cycles. Canada’s universal coverage and hospital capital budgets are more measured, yet procedure volumes benefit from aging demographics and rising diabetes prevalence.

Europe displays steady single-digit revenue growth as MDR compliance ensures high product quality and as national health systems favour cost-effectiveness metrics. Germany, France and the United Kingdom remain top spenders, while Southern and Eastern European countries are upgrading cath-lab fleets through EU infrastructure funds. The stents market share across Western Europe is tempered by price controls, but value-based procurement is beginning to reward technologies that shorten dual antiplatelet therapy and reduce rehospitalization.

Asia-Pacific is the largest incremental contributor to future unit demand, with China alone performing over 1 million coronary interventions in 2024. Reforms streamlining local approval for innovative devices are shortening launch timelines, although province-specific catalog pricing creates margin pressures. India’s national insurance scheme broadens access to PCI, while Japan maintains premium pricing for polymer-free and ultra-thin stents due to rapid ageing. Southeast Asian nations are scaling cardiac centers, and public-private partnerships in Indonesia and Vietnam are accelerating infrastructure deployment. Collectively, these trends anchor Asia-Pacific as the fastest-growing region within the stents market.

Competitive Landscape

The stents industry is moderately consolidated. The companies are leveraging broad coronary and peripheral portfolios and aggressive emerging-market expansion. Boston Scientific agreed to acquire Silk Road Medical for USD 1.26 billion to deepen its neurovascular franchise, while Teleflex announced a €760 million purchase of Biotronik’s vascular intervention arm to add specialty devices in lower-limb disease. Abbott’s investments in bioresorbable scaffolds and imaging integration sustain competitive differentiation.

Technology innovation is intense. Companies are pairing hydrophilic coatings with polymer-free drug reservoirs, and investing in AI-driven workflow tools that shorten procedure time. Drug-coated balloons remain a notable substitute threat for small-vessel disease and in-stent restenosis, prompting stent makers to prove superiority through head-to-head trials. Private-equity ownership of large cardiology practices is consolidating buyer power, nudging vendors toward multi-year value-based contracts. Cost-conscious health systems in Europe and parts of Asia are also encouraging price competition, although intellectual property around surface chemistry and scaffold geometry provides some insulation. Mid-size challengers are targeting white-space niches such as pediatric implants and fully degradable peripheral devices, elevating long-term innovation pressure in the stents market.